FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileDamora Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DMRA
Damora Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Damora Therapeutics, Inc. (DMRA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDMRA
DMRA
Damora Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DMRA
  1. Home
  2. Stocks
  3. Damora Therapeutics, Inc.

Damora Therapeutics, Inc.

🇺🇸DMRA•NASDAQ

Damora Therapeutics, Inc.

🇺🇸DMRA•NASDAQ
Market cap
$1.44B

Your view on DMRA

Mkt Cap
$1.44B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Damora Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Jennifer A. Jarrett
Headquarters
Building 23, Waltham, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Jennifer A. Jarrett
Headquarters
Building 23, Waltham, MA, US
Description

Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2.

Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Damora Therapeutics, Inc.. Starting points for Damora Therapeutics, Inc.: EPS -$4.72, beta 1.51 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Damora Therapeutics, Inc.. Trailing twelve-month EPS for Damora Therapeutics, Inc. stands at -$4.72. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Damora Therapeutics, Inc.. Damora Therapeutics, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold DMRA12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
NTRBNutriband Inc.HealthcareNASDAQ$59.8M
NTRBWNutriband Inc.HealthcareNASDAQ$76.8M
NTRRNeutra Corp.HealthcareOTC$291,790
NURPFNeuren Pharmaceuticals LimitedHealthcareOTC$1.1B
NUVBNuvation Bio Inc.HealthcareNYSE$1.3B
NUZ.AXNeurizon Therapeutics LimitedHealthcareASX—
NVAXNovavax, Inc.HealthcareNASDAQ$1.2B
NVCTNuvectis Pharma, Inc.HealthcareNASDAQ$666.8M
NWBONorthwest Biotherapeutics, Inc.HealthcareOTC$359.4M
NWPHFNewron Pharmaceuticals S.p.A.HealthcareOTC$239.5M
NXTCNextCure, Inc.HealthcareNASDAQ$29.5M
NYMXFNymox Pharmaceutical CorporationHealthcareOTC$4.8M
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Damora Therapeutics, Inc., and how their positions are changing. At a $1.44B market value, institutional positions materially move Damora Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Damora Therapeutics, Inc. executives and directors. Shares of Damora Therapeutics, Inc. have traded between $2.45 and $38.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Damora Therapeutics, Inc.. Coverage tracks Damora Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Damora Therapeutics, Inc.

DMRA AnalysisFair
Past
5
Growth
2
Health
5
Profit
1
Value
1